GEP20094606B - Indole-2 -carboxamidine derivatives as nmda receptor antagonists - Google Patents
Indole-2 -carboxamidine derivatives as nmda receptor antagonistsInfo
- Publication number
- GEP20094606B GEP20094606B GEAP20059893A GEAP2005009893A GEP20094606B GE P20094606 B GEP20094606 B GE P20094606B GE AP20059893 A GEAP20059893 A GE AP20059893A GE AP2005009893 A GEAP2005009893 A GE AP2005009893A GE P20094606 B GEP20094606 B GE P20094606B
- Authority
- GE
- Georgia
- Prior art keywords
- nmda receptor
- compounds
- indole
- receptor antagonists
- disorders
- Prior art date
Links
- NUNZGJKXTJMXGY-UHFFFAOYSA-N 1H-indole-2-carboximidamide Chemical class C1=CC=C2NC(C(=N)N)=CC2=C1 NUNZGJKXTJMXGY-UHFFFAOYSA-N 0.000 title 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 2
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000008736 traumatic injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0401523A HUP0401523A3 (en) | 2004-07-29 | 2004-07-29 | Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20094606B true GEP20094606B (en) | 2009-02-10 |
Family
ID=89985408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP20059893A GEP20094606B (en) | 2004-07-29 | 2005-07-21 | Indole-2 -carboxamidine derivatives as nmda receptor antagonists |
Country Status (21)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| JP2013519722A (ja) | 2010-02-16 | 2013-05-30 | ファイザー・インク | （ｒ）−４−（（４−（（４−（テトラヒドロフラン−３−イルオキシ）ベンゾ［ｄ］イソオキサゾール−３−イルオキシ）メチル）ピペリジン−１−イル）メチル）テトラヒドロ−２ｈ−ピラン−４−オール、５−ｈｔ４受容体の部分アゴニスト |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| SG10201510402WA (en) * | 2010-11-18 | 2016-01-28 | Univ Yale | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
| JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| US9669030B2 (en) * | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| JP7114594B2 (ja) | 2017-07-28 | 2022-08-08 | 武田薬品工業株式会社 | 複素環化合物 |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9726388D0 (en) * | 1997-12-12 | 1998-02-11 | Cerebrus Ltd | Chemical compounds |
| US6376530B1 (en) * | 1999-05-10 | 2002-04-23 | Merck & Co., Inc. | Cyclic amidines useful as NMDA NR2B antagonists |
| US6319944B1 (en) * | 1999-05-10 | 2001-11-20 | Merck & Co., Inc. | Aryl amidines, compositions containing such compounds and methods of use |
| GB0015488D0 (en) * | 2000-06-23 | 2000-08-16 | Merck Sharp & Dohme | Therapeutic agents |
| HU227197B1 (en) * | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| JP2004253425A (ja) * | 2003-02-18 | 2004-09-09 | Tdk Corp | 積層コンデンサ |
-
2004
- 2004-07-29 HU HU0401523A patent/HUP0401523A3/hu unknown
-
2005
- 2005-07-21 WO PCT/HU2005/000078 patent/WO2006010965A1/en not_active Ceased
- 2005-07-21 MX MX2007001052A patent/MX2007001052A/es active IP Right Grant
- 2005-07-21 AT AT05764412T patent/ATE427299T1/de not_active IP Right Cessation
- 2005-07-21 CA CA002574155A patent/CA2574155A1/en not_active Abandoned
- 2005-07-21 JP JP2007523161A patent/JP2008508248A/ja not_active Withdrawn
- 2005-07-21 CN CNA2005800247658A patent/CN1989103A/zh active Pending
- 2005-07-21 BR BRPI0513932-5A patent/BRPI0513932A/pt not_active IP Right Cessation
- 2005-07-21 EA EA200700365A patent/EA009981B1/ru not_active IP Right Cessation
- 2005-07-21 GE GEAP20059893A patent/GEP20094606B/en unknown
- 2005-07-21 AP AP2006003840A patent/AP2006003840A0/xx unknown
- 2005-07-21 US US11/658,787 patent/US20090048303A1/en not_active Abandoned
- 2005-07-21 KR KR1020077000263A patent/KR20070038502A/ko not_active Withdrawn
- 2005-07-21 AU AU2005266160A patent/AU2005266160A1/en not_active Abandoned
- 2005-07-21 EP EP05764412A patent/EP1773770B1/en not_active Expired - Lifetime
- 2005-07-21 DE DE602005013675T patent/DE602005013675D1/de not_active Expired - Fee Related
-
2006
- 2006-11-22 IL IL179485A patent/IL179485A0/en unknown
-
2007
- 2007-01-11 ZA ZA200700325A patent/ZA200700325B/en unknown
- 2007-01-17 TN TNP2007000016A patent/TNSN07016A1/en unknown
- 2007-02-22 MA MA29702A patent/MA28815B1/fr unknown
- 2007-02-27 NO NO20071109A patent/NO20071109L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005266160A1 (en) | 2006-02-02 |
| US20090048303A1 (en) | 2009-02-19 |
| ZA200700325B (en) | 2008-05-28 |
| NO20071109L (no) | 2007-02-27 |
| DE602005013675D1 (de) | 2009-05-14 |
| HUP0401523A3 (en) | 2007-05-02 |
| MX2007001052A (es) | 2007-04-16 |
| HU0401523D0 (en) | 2004-09-28 |
| EA200700365A1 (ru) | 2007-06-29 |
| CA2574155A1 (en) | 2006-02-02 |
| EA009981B1 (ru) | 2008-04-28 |
| CN1989103A (zh) | 2007-06-27 |
| IL179485A0 (en) | 2007-05-15 |
| ATE427299T1 (de) | 2009-04-15 |
| EP1773770A1 (en) | 2007-04-18 |
| KR20070038502A (ko) | 2007-04-10 |
| EP1773770B1 (en) | 2009-04-01 |
| BRPI0513932A (pt) | 2008-05-20 |
| JP2008508248A (ja) | 2008-03-21 |
| AP2006003840A0 (en) | 2006-12-31 |
| MA28815B1 (fr) | 2007-08-01 |
| WO2006010965A1 (en) | 2006-02-02 |
| TNSN07016A1 (en) | 2008-06-02 |
| HUP0401523A2 (en) | 2006-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20094606B (en) | Indole-2 -carboxamidine derivatives as nmda receptor antagonists | |
| TW200716121A (en) | Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists | |
| WO2004007481A3 (en) | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders | |
| WO2002074758A3 (en) | Novel amines as histamine-3 receptor ligands and their therapeutic applications | |
| TW200833328A (en) | 2-aza-bicyclo[3.1.0]hexane derivatives | |
| PL2152709T3 (pl) | Związki morfinanu | |
| TW200740789A (en) | Pyridine and pyrimidine derivatives as mGluR2 antagonists | |
| MX2009010505A (es) | Derivados de piridina y pirimidina como antagonistas de mglur2. | |
| GB0504828D0 (en) | Therapeutic agents | |
| CY1112727T1 (el) | Παραγωγα κυκλοβουτυλ αμινης βενζοθειαζολης και η χρηση αυτων ως προσδετες των υποδοχεων ισταμινης-3 | |
| MX2007010414A (es) | Derivados de piridin-2-carboxamida como antagonistas de mglur5. | |
| MXPA04000278A (es) | Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales. | |
| MX2010001486A (es) | Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl. | |
| TW200635903A (en) | Therapeutic agents | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| MX2009008527A (es) | Compuestos de amonio cuaternario y difenilmetilo utiles como antagonistas del receptor muscarinico. | |
| IL204064A (en) | Compounds 4-Formylphiprazine-1-Carboxamidine Efficacy as Muscarinic Receptor Antagonists | |
| PL1758853T3 (pl) | Antagoniści receptora glukagonu, wytwarzanie i zastosowania terapeutyczne | |
| PL1620425T3 (pl) | Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu | |
| SG154443A1 (en) | Piperidine derivatives as nk1 antagonists | |
| MX2008001606A (es) | Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. | |
| MY137272A (en) | Imidazole derivatives | |
| TW200726764A (en) | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | |
| WO2007067875A3 (en) | Pyridinyl sulfonamide modulators of chemokine receptors | |
| IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns |